CAMBRIDGE, Mass./PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. Judith Ng Cashin, M.D., has joined the company as Chief Medical Officer effective as of October 1, 2018.  

"Dr. Ng Cashin has extensive background in both infectious disease and dermatology and will be invaluable as we advance microbial-based drugs through clinical development," said AOBiome's President and CEO Todd Krueger. "She brings a wealth of experience to the team in both early and late stage drug development with major pharmaceutical companies where she managed clinical research, interacted with the FDA, and developed clinical and portfolio strategies. We look forward to the insight and depth of knowledge Judi brings to AOBiome."

Most recently, Dr. Ng Cashin served as Chief Scientific Officer at Syneos Health, a pharmaceutical services provider created by the merger of INC Research and inVentiv Health, where she led the integration of the therapeutic, medical, and scientific operations within product development and Phase 1-4 trial delivery.  Prior to Syneos, Dr. Ng Cashin served as the Vice President of Medical Strategy and then of Advisory Services for IQVIA, formerly Quintiles, a management consultancy focused on biopharma and the healthcare industry. Her experience also includes nine years with GlaxoSmithKline (GSK) in senior medical leadership roles including, Vice President of Medical Excellence and Quality, Vice President and Global Head, Infectious Diseases Medicines Development Center, as well as Vice President of Stiefel Laboratories, GSK's dermatology franchise focusing on acne treatments and anti-infectives.

Dr. Ng Cashin is currently a board member of the Drug Information Association (DIA). She earned her M.D. from Rush Medical College and trained in Internal Medicine at the University of Chicago. She subsequently undertook her sub-specialty fellowship training at the University of North Carolina at Chapel Hill in infectious diseases and hematology/oncology after which she served on the clinical faculty.

"Joining the AOBiome team is an exciting opportunity to advance the application of ammonia oxidizing bacteria to the treatment of human disease.  Reestablishing the symbiotic relationship between bacteria and human to restore important biologic and biochemical processes is a growing area in science and medicine.  At AOBiome, we have the potential to bring a first-in-class live biotherapeutic to patients.  With my experience in microbiology, infectious diseases, dermatology, and drug development, I believe I can help lead the company toward this goal," said Dr. Ng Cashin.


About Ammonia Oxidizing Bacteria (AOB) 
AOBiome's AOB platform is a patented, proprietary, topical and intranasal formulation incorporating a single strain of beneficial AOB, Nitrosomonas eutropha. The platform is designed to repopulate the skin or nasal microbiome with AOB. Once deployed, AOB produces nitric oxide, a signaling molecule known to regulate inflammation and vasodilation.

Contacts:

For Media Inquiries:
Ryo Imai
212-213-0006, ext. 315
rimai@burnsmc.com